Business Context and Reporting Period
Company: Labcorp Holdings Inc. (LHI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A global leader in laboratory services operating through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). Dx contributed approximately 78% of revenues, while BLS contributed 22%.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $3,537.6 million | $3,345.1 million |
| Net Earnings (Attributable to LHI) | $277.8 million | $212.8 million |
| Diluted EPS | $3.35 | $2.52 |
| Operating Income | $380.8 million | $326.0 million |
| Operating Margin | 10.8% | 9.7% |
| Net Cash from Operating Activities | $191.5 million | $18.5 million |
| Cash and Cash Equivalents (End of Period) | $981.1 million | $369.4 million |
| Total Debt (Short-term + Long-term) | $6,334.1 million | $5,584.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5.8% year-over-year, driven by organic growth (3.1%), acquisitions (1.4%), and favorable foreign currency translation (1.3%).
- Profitability: Net earnings rose 30.5% to $277.8 million. The effective tax rate decreased to 13.1% from 22.6% due to discrete tax benefits from restructuring foreign entities.
- Segment Performance:
- Dx: Revenues up 5.0%; Operating income up 7.3% to $458.7 million.
- BLS: Revenues up 8.2%; Operating income up 12.9% to $120.7 million.
- Cash Flow: Operating cash flow surged to $191.5 million from $18.5 million, primarily due to higher cash earnings and improved working capital management.
- Debt Structure: The company entered a new $750.0 million Term Loan in March 2026 to repay maturing short-term debt. Total debt increased due to this new borrowing and acquisition-related contingent consideration.
Guidance, Outlook, and Risks
- Acquisitions: Completed acquisitions totaling $312.0 million in consideration during Q1 2026. A pending acquisition of select assets from Parkview Health System (approx. $165.0 million) is expected to close in 2026.
- Capital Allocation: Repurchased $98.0 million of common stock in Q1 2026. $732.4 million remains available under the current repurchase authorization. Declared a quarterly dividend of $0.72 per share.
- Regulatory Environment: The U.S. government enacted the "One Big Beautiful Bill Act" (OBBBA) in July 2025, which may impact Medicaid and federal funding. Management currently believes this will not have a material impact on future results but is monitoring the situation.
- Legal Contingencies:
- Texas Medicaid: A qui tam lawsuit regarding "best price" regulations is pending review by the Texas Supreme Court.
- AMCA Data Incident: A class action settlement regarding the 2019 security incident at a third-party collection agency was reached in March 2026, subject to court approval.
- Ravgen Patent: The company is appealing a jury verdict finding willful patent infringement, which included damages and ongoing royalties.
- Liquidity: Management believes operating cash flows, the $1,000.0 million revolving credit facility, and the new Term Loan provide sufficient liquidity for the next 12 months.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with leverage ratios under the new 2026 Term Loan and revolving credit facility.
- Acquisition Integration: Monitor the closing and integration of the Parkview Health System assets and the impact of Q1 2026 acquisitions on future organic growth rates.
- Legal Reserves: Track the status of the Texas Medicaid Supreme Court review and the final court approval of the AMCA class action settlement.
- Regulatory Impact: Assess the long-term impact of the OBBBA on Medicaid reimbursement rates and utilization volumes.
- Foreign Currency: Evaluate the impact of currency fluctuations on the BLS segment, which saw significant revenue growth driven by favorable translation.